Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: Subanalysis of REVEAL and the open-label extension study

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 5, 2013, Pages 634-642

  Papp, K ^a   Menter, A ^b   Poulin, Y ^c   Gu, Y ^d   Sasso, E H ^d  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b BAYLOR RESEARCH INSTITUTE   (United States)

^c Centre Dermatologique du Quebec Metropolitain   (Canada)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ADULT; ALLERGIC REACTION; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION; LUPUS VULGARIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROBABILITY; PSORIASIS; TREATMENT OUTCOME;

EID: 84876147894     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04515.x     Document Type: Article

References (26)

1. Kimball AB, Gieler U, Linder D, Sampogna F, Warren DB, Augustin M,. Psoriasis: Is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989-1004.
2. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
3. Gottlieb AB, Chao C, Dann F,. Psoriasis comorbidities. J Dermatolog Treat 2008; 19: 5-21.
4. Channual J, Wu JJ, Dann FJ,. Effects of tumor necrosis factor-α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Therapy 2009; 22: 61-73.
5. Kimball AB, Guerin A, Latremouille-Viau D, et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 2010; 123: 350-357.
6. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975.
7. Gordon KB, Gottlieb AB, Leonardi CL, et al.; for Etanercept Psoriasis Study Group. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006; 17: 9-17.
8. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56: 598-603.
9. Ortonne J-P, Griffiths CEM, Dauden E, et al. Efficacy and safety of continuous versus paused etanercept in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Expert Rev Dermatol 2008; 3: 657-665.
10. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-31.e15.
11. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
12. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
13. Gordon K, Blum R, Papp K, et al. Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized clinical trial. Psoriasis Forum 2007; 13: 4-11.
14. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
15. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH,. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241-251.
16. Papp K, Crowley J, Ortonne J-P, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011; 164: 434-441.
17. Asahina A, Nakagawa H, Etoh T, Ohtsuki M,. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
18. HUMIRA [package insert]. Abbott Laboratories, North Chicago, IL, 2011.
19. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M,. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008; 216: 260-270.
20. Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM,. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010; 162: 1349-1358.
21. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
22. European Medicines Agency. Assessment report for Stelara. [WWW document]. DocRef: EMEA/CHMP/29255/2009. URL http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Public-assessment-report/human/000958/WC500058511.pdf (last accessed 7 March 2012).
23. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
24. Reich K, Pohl C, Wozel C, et al. Infliximab is associated with greater improvement in health related quality of life versus methotrexate for moderate-to-severe plaque-type psoriasis-the Restore1 trial. Abstract P1187 presented at: 18th Congress of the European Academy of Dermatology and Venereology; October 7-11, 2009; Berlin, Germany.
25. Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365: 1586-1596.
26. Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-1468.